title: Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats.
abstract: We investigated whether long-term infusion of kallikrein would attenuate renal injury in salt-induced hypertension in Dahl salt-sensitive rats. A subdepressor dose of purified rat urinary kallikrein (700 ng/d IV) was infused by osmotic minipump for 4 weeks in male Dahl salt-sensitive rats fed a high salt (2% NaCl) diet. This dose did not affect the time-dependent elevation of blood pressure; however, urinary protein excretion was significantly decreased, and glomerular filtration rate was increased. These beneficial effects were reflected morphologically by an attenuation of glomerulosclerotic lesions and tubular injury seen in the hypertensive Dahl salt-sensitive rats. Kallikrein infusion increased urinary excretion of bradykinin and stimulated excretion of cyclic GMP, suggesting that the kallikrein-kinin-prostaglandin and nitric oxide axes were enhanced by rat urinary kallikrein infusion. The alterations induced by kallikrein infusion were potentiated by the concomitant administration of the angiotensin-converting enzyme inhibitor alacepril. These studies indicated that long-term replacement with rat tissue kallikrein attenuates renal injury in hypertensive Dahl salt-sensitive rats.
authors.affiliation: Second Department of Medicine, University of Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Uehara
authors.forename: N
authors.initials: N
authors.lastname: Hirawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kawabata
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: N
authors.initials: N
authors.lastname: Ohshima
authors.forename: K
authors.initials: K
authors.lastname: Oka
authors.forename: T
authors.initials: T
authors.lastname: Ikeda
authors.forename: A
authors.initials: A
authors.lastname: Goto
authors.forename: T
authors.initials: T
authors.lastname: Toyo-oka
authors.forename: K
authors.initials: K
authors.lastname: Kizuki
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D001920:Bradykinin / Q000652:urine; D002216:Captopril / Q000031:analogs & derivatives / Q000494:pharmacology; D003401:Creatine / Q000097:blood / Q000652:urine; D006152:Cyclic GMP / Q000652:urine; D015777:Eicosanoids / Q000652:urine; D006439:Hemodynamics / Q000187:drug effects; D006973:Hypertension / Q000139:chemically induced* / Q000473:pathology* / Q000503:physiopathology; D007610:Kallikreins / Q000008:administration & dosage* / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects* / Q000473:pathology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012965:Sodium Chloride; D013997:Time Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D015777:Eicosanoids; D012965:Sodium Chloride; D002216:Captopril; D007610:Kallikreins; D006152:Cyclic GMP; D003401:Creatine; D001920:Bradykinin; C046835:alacepril